Changes in intraocular pressure following intravitreal dexamethasone implant in patients with history of glaucoma filtration surgery

被引:0
|
作者
Lee, Dong Kyu [1 ]
Lee, Joo Yong [2 ]
Woo, Se Joon [3 ]
Ji, Yong Sok [4 ]
Lee, Christopher Seungkyu [1 ]
机构
[1] Yonsei Univ, Coll Med, Severance Eye Hosp, Dept Ophthalmol,Inst Vis Res, Yonsei Ro 50 1, Seoul 03722, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Seongnam, South Korea
[4] Chonnam Natl Univ, Chonnam Natl Univ Hosp, Dept Ophthalmol, Coll Med, Gwangju, South Korea
基金
新加坡国家研究基金会;
关键词
Intravitreal dexamethasone implant; Intraocular pressure elevation; Glaucoma filtration surgery; Steroid responder; HUMAN TRABECULAR MESHWORK; OCULAR HYPERTENSION; STEROIDS; OZURDEX; 3-YEAR; SYSTEM; TRIAL;
D O I
10.1007/s00417-024-06468-z
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose This study aimed to evaluate changes in intraocular pressure following intravitreal dexamethasone implant injection, specifically in patients undergoing glaucoma filtration surgery. Methods The degree of increase in intraocular pressure was compared retrospectively among three groups. Group 1 comprised patients who underwent prior glaucoma filtration surgery (54 eyes). Group 2 included patients with or suspected glaucoma without such surgical history (20 eyes). Group 3 included patients without glaucoma (33 eyes). Pressure measurements were taken before the injection and at 1, 2, 3, and 6 months post-injection. A subgroup analysis was performed for pressure > 35 mmHg, > 30 mmHg, > 25 mmHg, and a difference > 10 mmHg between the peak and baseline pressure. Results Group 1 consistently displayed lower pressures compared with Group 2, with significant difference at both 1- and 6-month post-injections (15.09 mmHg vs. 18.10 mmHg, P = 0.042 and 13.91 mg vs. 17.25 mmHg, P = 0.040). The proportion of patients in Group 1 and Group 3 with pressures > 25 mmHg, > 30 mmHg, and a difference > 10 mmHg did not significantly differ (15.6% vs. 9.5%, P = 0.231; 3.1% vs. 2.3%, P = 0.867; and 17.1% vs. 7.1%, P = 0.231). Notably, Group 2 exhibited a significantly higher proportion within each category (> 25 mmHg, 24.0%; > 30 mmHg, 20.0%; > 10 mmHg difference, 28.0%). Conclusion Intravitreal dexamethasone implant did not increase the risk of elevated intraocular pressure in patients with a history of glaucoma filtration surgery compared with patients with suspected glaucoma; the risk was similar to those without glaucoma.
引用
收藏
页码:2845 / 2850
页数:6
相关论文
共 50 条
  • [21] Short-Term Safety and Efficacy of PreserFlo™ Microshunt in Patients with Refractory Intraocular Pressure Elevation After Dexamethasone Implant Intravitreal Injection
    Bourauel, Leonie
    Petrak, Michael
    Holz, Frank G.
    Mercieca, Karl
    Weber, Constance
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (02)
  • [22] Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification
    Furino, Claudio
    Boscia, Francesco
    Recchimurzo, Nicola
    Sborgia, Carlo
    Alessi, Giovanni
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2014, 24 (03) : 387 - 391
  • [23] Intravitreal Dexamethasone Implant in Patients with Persistent Macular Edema of Variable Etiologies
    Sorkin, Nir
    Loewenstein, Anat
    Habot-Wilner, Zohar
    Goldstein, Michaela
    OPHTHALMOLOGICA, 2014, 232 (02) : 83 - 91
  • [24] Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema
    Dutra Medeiros, Marco
    Postorino, Maurizio
    Navarro, Rafael
    Garcia-Arumi, Jose
    Mateo, Carlos
    Corcostegui, Borja
    OPHTHALMOLOGICA, 2014, 231 (03) : 141 - 146
  • [25] Intravitreal dexamethasone implant for noninfectious uveitis in Chinese patients
    Zeng, Shun
    Yang, Li
    Bai, Feng
    Liu, Tao
    Liu, Xiaoli
    INTERNATIONAL OPHTHALMOLOGY, 2022, 42 (07) : 2063 - 2069
  • [26] Intravitreal dexamethasone implant for noninfectious uveitis in Chinese patients
    Shun Zeng
    Li Yang
    Feng Bai
    Tao Liu
    Xiaoli Liu
    International Ophthalmology, 2022, 42 : 2063 - 2069
  • [27] Evaluation of the Effect of Intravitreal Dexamethasone (Ozurdex®) Implant on Intraocular Pressure in Vitrectomized and Non-Vitrectomized Eyes with Macular Edema
    Garli, Murat
    Kurna, Sevda Aydin
    Acikalin, Banu
    Ceviker, Ayse
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2021, 51 (06): : 365 - 372
  • [28] Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema
    Bansal, Pooja
    Agarwal, Aniruddha
    Gupta, Vishali
    Singh, Ramandeep
    Gupta, Amod
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2015, 63 (05) : 416 - 422
  • [29] Persistent vitreous hemorrhage after intravitreal injection of dexamethasone intravitreal implant in patients with diabetic macular edema
    Li, Meng-Syuan
    Sheu, Shwu-Jiuan
    TAIWAN JOURNAL OF OPHTHALMOLOGY, 2019, 9 (04) : 280 - 283
  • [30] Aqueous Humour Cytokine Changes with Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema
    Figueras-Roca, Marc
    Sala-Puigdollers, Anna
    Alforja, Socorro
    Torras, Josep
    Peraza-Nieves, Jorge
    Zarranz-Ventura, Javier
    Adan Civera, Alfredo
    Molins, Blanca
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (08) : 1203 - 1210